StonvexLoading…
StonvexStonvexStonvexCore line items from CHDN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $2.93B | $2.73B | $2.46B | $1.81B |
Operating Income | $683.80M | $709.00M | $564.00M | $321.80M |
Net Income | $383.00M | $426.80M | $417.30M | $439.40M |
EPS (Diluted) | $5.29 | $5.68 | $5.49 | $5.71 |
Total Assets | $7.48B | $7.28B | $6.96B | $6.21B |
Total Liabilities | $6.43B | $6.17B | $6.06B | $5.66B |
Cash & Equivalents | $200.60M | $175.50M | $144.50M | $129.80M |
Free Cash Flow OCF − CapEx | $699.60M | $688.10M | $527.60M | $460.60M |
Shares Outstanding | 69.60M | 73.50M | 74.50M | 74.80M |